NIRFLI with ICG

PreclinicalSmall molecule

TThe University of Texas Health Science Center, Houston

NIRFLI with ICG is one of 75 small molecule programs targeting Tic Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tic DisorderActive, not recruiting

LymphedemaActive, not recruiting

Tic DisorderPreclinical

Active, not recruiting

LymphedemaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

71 competitors in Tic Disorder

#DrugCompanyPhaseTrials

Cymbalta

Alnylam Pharmaceuticals

Approved

2 2

Lithobid

SSolvay Pharmaceuticals

Approved

1 3

Buspar

Bristol-Myers Squibb

Phase 3

1 4

Abilify

Otsuka

Phase 3

6 5

Vitrakvi

Bayer

Phase 2

2 6

Lynparza

AstraZeneca

Phase 2

2 7

Ibrance

Pfizer

Phase 2

2 8

Balversa

Johnson & Johnson

Phase 2

2 9

Retevmo

Eli Lilly

Phase 2

2 10

Haldol

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tic Disorder1 trial

Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders

Enrolling by invitation·TThe University of Texas Health Science Center, Houston··NCT00833599·283 enrolled

Lymphedema1 trial

Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-Related Lymphedema

Completed·TTactile Medical·Phase 1/2·NCT02946021·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for NIRFLI with ICG. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NIRFLI with ICG compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NIRFLI with ICG. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The University of Texas Health Science Center, Houston company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe University of Texas Health Science Center, Houston

NIRFLI with ICG

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tic Disorder1 trial

Lymphedema1 trial

References

Drug Info

Quick Facts

Related News